It was a pleasure to talk to Stephen Hanauer (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around his presentation on ‘EMERGING IBD THERAPIES’ which was presented at the virtual 2021 Crohn’s & Colitis Congress.
Questions
- Could you give us a brief overview of the current treatment options for patients with moderate‑to‑severe ulcerative colitis and Crohn’s disease? (0:18)
- What are the current unmet needs in the treatment of patients who have had an inadequate response to prior treatment with TNF inhibitors? (1:55)
- How do you expect the use of IL‑12/23 inhibitors to develop in the coming years? (3:01)
- What are the potential advantages of oral JAK inhibitors and S1P agents, and what is the current status of their development? (3:54)
- What remaining issues need to be addressed in the treatment of patients with moderate‑to‑severe ulcerative colitis and Crohn’s disease? (5:38)
Disclosures: Stephen Hanauer has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
